Intrathecal AAV serotype 9-mediated delivery of shRNA against TRPV1 attenuates thermal hyperalgesia in a mouse model of peripheral nerve injury.

@article{Hirai2014IntrathecalAS,
  title={Intrathecal AAV serotype 9-mediated delivery of shRNA against TRPV1 attenuates thermal hyperalgesia in a mouse model of peripheral nerve injury.},
  author={Takashi Hirai and Mitsuhiro Enomoto and Hidetoshi Kaburagi and Shinichi Sotome and Kie Yoshida-Tanaka and Madoka Ukegawa and Hiroya Kuwahara and Mariko Yamamoto and Mio Tajiri and Haruka Miyata and Yukihiko Hirai and Makoto Tominaga and Kenichi Shinomiya and Hidehiro Mizusawa and Atsushi Okawa and Takanori Yokota},
  journal={Molecular therapy : the journal of the American Society of Gene Therapy},
  year={2014},
  volume={22 2},
  pages={409-419}
}
Gene therapy for neuropathic pain requires efficient gene delivery to both central and peripheral nervous systems. We previously showed that an adenoassociated virus serotype 9 (AAV9) vector expressing short-hairpin RNA (shRNA) could suppress target molecule expression in the dorsal root ganglia (DRG) and spinal cord upon intrathecal injection. To evaluate the therapeutic potential of this approach, we constructed an AAV9 vector encoding shRNA against vanilloid receptor 1 (TRPV1), which is an… CONTINUE READING
Highly Cited
This paper has 33 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…